Glenmark to focus on becoming branded company, says Glenn Saldanha

Glenmark Pharmaceuticals, having navigated recent challenges, is shifting its focus to branded products for higher profit margins. The company, aiming for a 12%-15% growth rate, divested its active pharmaceutical ingredient business to concentrate on branded pharmaceuticals, particularly in respiratory, dermatology, and oncology.